Manufacturing USP adds Tamiflu, Trulicity to vulnerable list as upstream analysis reshapes supply concerns BioSpaceAlmost half of the top 100 medicines vulnerable to supply disruptions in the U.S.ManufacturingRead full story pharminent April 13, 2026 (Last updated: April 13, 2026) BioSpace Almost half of the top 100 medicines vulnerable to supply disruptions in the U.S. ManufacturingRead full story Post navigation Previous: Allogene stock sails after CAR T clears residual lymphoma in early data cutNext: FDA Reminds More Than 2,200 Sponsors and Researchers to Disclose Trial Results Related Stories Manufacturing BMS banks on Texas for $2.3bn multi-modal manufacturing facility pharminent August 11, 2026 Manufacturing AsymBio to secure $184m to support growth in biologics manufacturing pharminent August 5, 2026 Manufacturing Lilly and Resilience invest $750M in diabetes and obesity drug device supply pharminent July 31, 2026
